Voya Investment Management LLC Sells 187,840 Shares of Insmed, Inc. $INSM

Voya Investment Management LLC cut its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 46.1% during the 3rd quarter, HoldingsChannel reports. The fund owned 219,839 shares of the biopharmaceutical company’s stock after selling 187,840 shares during the quarter. Voya Investment Management LLC’s holdings in Insmed were worth $31,659,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in INSM. ORG Partners LLC raised its position in Insmed by 220.2% in the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 196 shares during the period. Hilltop National Bank bought a new position in shares of Insmed during the second quarter valued at about $28,000. FNY Investment Advisers LLC bought a new position in shares of Insmed during the second quarter valued at about $33,000. LRI Investments LLC purchased a new position in shares of Insmed in the second quarter worth about $59,000. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of Insmed by 65.6% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 664 shares of the biopharmaceutical company’s stock valued at $67,000 after acquiring an additional 263 shares during the last quarter.

Analyst Upgrades and Downgrades

INSM has been the subject of several recent research reports. Cowen set a $241.00 price objective on Insmed in a research report on Thursday. Wells Fargo & Company set a $195.00 price target on shares of Insmed in a report on Thursday. Bank of America increased their price target on shares of Insmed from $142.00 to $187.00 and gave the company a “buy” rating in a research report on Monday, October 27th. Wedbush set a $203.00 price objective on shares of Insmed in a research report on Thursday. Finally, HC Wainwright lowered their price objective on shares of Insmed from $240.00 to $230.00 and set a “buy” rating for the company in a research note on Thursday. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $205.41.

Insider Transactions at Insmed

In related news, insider Michael Alexander Smith sold 27,130 shares of the company’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $183.78, for a total value of $4,985,951.40. Following the transaction, the insider owned 54,902 shares in the company, valued at $10,089,889.56. The trade was a 33.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Elizabeth M. Anderson sold 10,000 shares of the stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $195.87, for a total transaction of $1,958,700.00. Following the sale, the director directly owned 63,729 shares in the company, valued at $12,482,599.23. This trade represents a 13.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 157,829 shares of company stock worth $30,266,463 over the last quarter. Corporate insiders own 3.00% of the company’s stock.

Insmed Price Performance

INSM stock opened at $174.84 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63. The firm has a 50 day moving average price of $187.66 and a 200-day moving average price of $143.51. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $212.75. The firm has a market capitalization of $37.29 billion, a price-to-earnings ratio of -28.25 and a beta of 1.01.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The company had revenue of $142.34 million for the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The firm’s quarterly revenue was up 52.4% on a year-over-year basis. During the same period last year, the business earned ($1.27) EPS. Equities research analysts forecast that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insmed News Summary

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Unusual bullish options activity: traders bought a large block of INSM calls (≈6,582 contracts, +78% vs. average), signaling speculative or hedge interest that can support a bounce after the sell‑off.
• Positive Sentiment: Pipeline add — Insmed announced it is adding a new monoclonal‑antibody asset while reshaping its pipeline, which investors may view as a constructive move to offset the terminated sinus program. INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset
• Neutral Sentiment: Analysts trimmed targets but mostly stayed constructive — TD Cowen cut its target to $241 and Guggenheim trimmed to $221 while maintaining buy ratings; these lower targets temper upside but keep institutional support. Benzinga analyst note
• Negative Sentiment: Clinical failure and program termination: a Phase IIb trial in chronic rhinosinusitis showed no benefit, leading Insmed to discontinue development of the drug — the principal trigger for the multi‑day share plunge and elevated volatility. High‑flying Insmed stumbles with rhinosinusitis trial failure for Brinsupri
• Negative Sentiment: Market reaction and commentary: coverage noted a near‑20% drop after hours and broad analyst/media focus on the failure; sell‑side and floor commentary (Mizuho/Barron’s) emphasized the stock’s sharp decline. Insmed Stock Plummets 19%
• Negative Sentiment: Analyst EPS downgrade: HC Wainwright cut FY2028 EPS estimates (now $3.15 from $3.42), signaling reduced near‑term earnings expectations tied to program changes and greater uncertainty.
• Negative Sentiment: Insider sale: CEO William Lewis sold 10,699 shares at an average ~$167 on Dec. 18 (SEC filing), reducing his stake ~3.4% — insider selling often raises investor concern when timed near volatile news. SEC Form 4 — William Lewis sale

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.